EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Nanomedicine Solutions for Alzheimer’s Disease: A Critical Review of Therapeutic Nanoparticle Strategies

Teboho E Tutubala, Ayodeji O Egunlusi, David Fisher, Admire Dube iD, Jacques Joubert iD

ACS Omega · 18.11.2025 · 10 (45) · 53633-53657

DOI: 10.1021/acsomega.4c04887 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ACS Omega, online erschienen am 07.11.2025. Verfasst von Teboho E Tutubala und 4 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Pharmaceutical Chemistry, School of Pharmacy, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 228 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: South African Medical Research Council, Perivoli Africa Research Center, University of Bristol.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a debilitating disorder marked by progressive memory and cognitive function loss. Current treatments, including acetylcholinesterase and N-methyl-d-aspartate receptor inhibitors, offer symptomatic relief but lack disease-modifying effects. The recent approval of aducanumab, an antibody clearing amyloid beta plaques, brings hope, though its therapeutic benefits are controversial. AD's etiology is multifactorial, involving over 40 genetic variants, and remains poorly defined. Nanotechnology offers a promising avenue for optimized drug candidates, addressing challenges such as solubility, stability, and blood-brain barrier permeation. This review explores nanoformulations targeting key AD aspects, including amyloid beta, Tau protein, oxidative stress, and neuroinflammation. Notably, multifunctional nanocarriers present a comprehensive approach, demonstrating the potential for effective AD therapy. Despite extensive research, only a small fraction of these studies progress to clinical trials. Continuous nanomedicine research is poised to play a vital role in future AD management, providing innovative solutions to this devastating disease.

Autor:innen und Institutionen

  • Discipline of Pharmaceutical Chemistry, School of Pharmacy, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa.
  • Division of Pharmaceutical Chemistry, Faculty of Pharmacy, Rhodes University, PO Box 94, Makhanda 6140, South Africa.
  • Department of Medical Biosciences, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa.
  • Discipline of Pharmaceutics, School of Pharmacy, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa.

ORCID-Profile: Admire Dube, Jacques Joubert

Förderung

  • South African Medical Research Council
  • Perivoli Africa Research Center, University of Bristol

Zitieren

APA

Tutubala, T. E., Egunlusi, A. O., Fisher, D., Dube, A., & Joubert, J. (2025). Nanomedicine Solutions for Alzheimer’s Disease: A Critical Review of Therapeutic Nanoparticle Strategies. ACS Omega, 10(45), 53633-53657. https://doi.org/10.1021/acsomega.4c04887

Vancouver

Tutubala TE, Egunlusi AO, Fisher D, Dube A, Joubert J. Nanomedicine Solutions for Alzheimer’s Disease: A Critical Review of Therapeutic Nanoparticle Strategies. ACS Omega. 2025;10(45):53633-53657. doi:10.1021/acsomega.4c04887

BibTeX
@article{Tutubala2025,
  author = {Tutubala, Teboho E and Egunlusi, Ayodeji O and Fisher, David and Dube, Admire and Joubert, Jacques},
  title = {Nanomedicine Solutions for Alzheimer’s Disease: A Critical Review of Therapeutic Nanoparticle Strategies},
  journal = {ACS Omega},
  year = {2025},
  volume = {10},
  number = {45},
  pages = {53633--53657},
  doi = {10.1021/acsomega.4c04887}
}
Kostenlos starten →